Theranostics Market

Theranostics Market - Size, Outlook, and
Opportunity Analysis, 2018 – 2026
Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also
known
as
companion
diagnostics,
integrated
medicine,
Dx/Rx
partnering,
and
pharmacodiagnostics. Implementation of theranostics into the patient care plan (in case of
selected diseases for which diagnostic tests are available along with respective therapy) may
turn into personalized therapy, which could further improve medical outcomes.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2043
Theranostics include use of specific diagnostic test, which shows a particular molecular target
on a tumor or any other disease causing agent. Any disease pathophysiology involves specific
biological pathways, which are targeted with the help of diagnostic tests. Diagnostic images of
the particular molecule then identifies presence of the specific mutation or receptors (in case of
cancer), which can be targeted with the help of therapeutic agents. This approach avoids trial
and error treatment and could be used to offer patient specific treatment at the right time.
Accurate dose calibration and precisely targeted approach could highly be useful in management
of chronic diseases such as cancer.
For instance, neuro endocrine tumors can be diagnosed to assess extent of disease via PET-CT
(Positron Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive
positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor cell membrane, and
is injected through vein, which travels and binds to the SSTR2 indication the presence of tumor
on PET scan. Furthermore, Ga-68 can be replaced by a therapeutic agent to target the tumor.
Global Theranostics Market Drivers:Development of novel companion diagnostic tests to be used with available treatment options is
expected to boost the global theranostics market growth over the forecast period. Leading
manufacturers are engaged in introduction of novel companion diagnostic tests in market. For
instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA)
approved extended RAS panel for identification of patients eligible for treatment of metastatic
colorectal cancer with Vectibix (panitumumab) in 2017.
Increasing adoption of companion diagnostic tests by laboratories is further expected to foster
global theranostics market growth over the forecast period. BloodCenter of Wisconsin's
Diagnostic Laboratories started offering Abbott RealTime IDH1 assay for patients with acute
myeloid leukemia (AML) in July 2018. Moreover, Cancer Genetics, Inc. started offering FDA
approved companion diagnostic Thermo Fisher Scientific's Oncomine Dx Target - the first NextGeneration Sequencing (NGS)-based Companion Diagnostic (CDx) test in 2017. Laboratory
Corporation of America Holdings launched OmniSeq Advance in partnership with OmniSeq for
tumor cancers in June 2018.
Report includes chapters which deeply display the following deliverable about industry :
• Theranostics Market Research Objective and Assumption
• Theranostics Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Theranostics Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Theranostics Market, By Regions
• Theranostics Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Theranostics Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Theranostics Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Theranostics Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2043
Partnerships and collaborations by leading manufacturers to develop innovative companion
diagnostics is expected to foster global theranostics market growth over the forecast period. For
instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a partnership for development,
regulatory support, and commercialization of companion diagnostics (CDx) in January 2018.
Moreover, Qiagen, Inc., and Freenome partnered in June 2018, to accelerate the development
and commercialization of Next-Generation Sequencing (NGS) tests to enable precision medicine
in cancer treatment.
Pierre Fabre and Roche have been working on development of a robust prototype
immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug
candidate which they are developing together) and extended this collaboration in May 2018.
Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to
develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic
mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to
support global theranostics market growth over the forecast period.
Global Theranostics Market Regional Insights:North America is expected to witness significant growth in the global theranostics market over
the forecast period. Presence of leading manufacturers, collaborations, robust research, and
development activities, and increasing adoption of companion diagnostics is expected to support
global theranostics market growth over the forecast period. Biocartis Group NV and Amgen, Inc.
partnered to develop companion diagnostic test for Amgen's drug Vectibix (panitumumab) in
2017. For instance, Genome Canada launched a national initiative for clinical implementation of
precision health in June 2018, which would ultimately impact global theranostics market
growth over the forecast period.
Asia Pacific theranostics market is expected to witness significant growth over the forecast
period, owing to collaborations in the region by global organizations and increasing awareness
regarding companion diagnostics. For instance, Qiagen collaborated with Japan based clinical
lab testing company, SRL, Inc. for introduction of new companion diagnostics with new drug
approvals in August 2018.
Key players of Global Theranostics Market:Key players operating in the global theranostics market include Thermo Fisher Scientific, Inc.,
Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann LA-Roche
Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation
Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2043
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also known as companion diagnostics, integrated medicine, Dx/Rx partnering, and pharmacodiagnostics.

Download Report